Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events (BMC Infectious Diseases)

Sotrovimab neutralizing SARS-CoV-2 remained effective at the advent of B.1 lineage of the Omicron variant in outpatients. Primarily for hospitalized patients, however, the Japanese government regulated to admi...